Chemical Validation of Phosphodiesterase C as a Chemotherapeutic Target in Trypanosoma cruzi , the Etiological Agent of Chagas' Disease
- 1 September 2010
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 54 (9) , 3738-3745
Abstract
Trypanosoma cruzi phosphodiesterase (PDE) C (TcrPDEC), a novel and rather unusual PDE in which, unlike all other class I PDEs, the catalytic domain is localized in the middle of the polypeptide chain, is able to hydrolyze cyclic GMP (cGMP), although it prefers cyclic AMP (cAMP), and has a FYVE-type domain in its N -terminal region (S. Kunz et al., FEBS J. 272: 6412-6422, 2005). TcrPDEC shows homology to the mammalian PDE4 family members. PDE4 inhibitors are currently under development for the treatment of inflammatory diseases, such as asthma, chronic pulmonary diseases, and psoriasis, and for treating depression and serving as cognitive enhancers. We therefore tested a number of compounds originally synthesized as potential PDE4 inhibitors on T. cruzi amastigote growth, and we obtained several useful hits. We then conducted homology modeling of T. cruzi PDEC and identified other compounds as potential inhibitors through virtual screening. Testing of these compounds against amastigote growth and recombinant TcrPDEC activity resulted in several potent inhibitors. The most-potent inhibitors were found to increase the cellular concentration of cAMP. Preincubation of cells in the presence of one of these compounds stimulated volume recovery after hyposmotic stress, in agreement with their TcrPDEC inhibitory activity in vitro , providing chemical validation of this target. The compounds found could be useful tools in the study of osmoregulation in T. cruzi . In addition, their further optimization could result in the development of new drugs against Chagas' disease and other trypanosomiases.Keywords
This publication has 36 references indexed in Scilit:
- Cyclic AMP intoxication of macrophages by a Mycobacterium tuberculosis adenylate cyclaseNature, 2009
- Design, Synthesis, and Structure−Activity Relationship, Molecular Modeling, and NMR Studies of a Series of Phenyl Alkyl Ketones as Highly Potent and Selective Phosphodiesterase-4 InhibitorsJournal of Medicinal Chemistry, 2008
- The effect of different electrostatic potentials on docking accuracy: A case study using DOCK5.4Bioorganic & Medicinal Chemistry Letters, 2008
- Homology modeling and examination of the effect of the D92E mutation on the H5N1 nonstructural protein NS1 effector domainJournal of Molecular Modeling, 2007
- Cyclic Nucleotide Signaling Mechanisms in Trypanosomes: Possible Targets for Therapeutic AgentsMolecular Interventions, 2007
- A FYVE‐containing unusual cyclic nucleotide phosphodiesterase from Trypanosoma cruziThe FEBS Journal, 2005
- The Amber biomolecular simulation programsJournal of Computational Chemistry, 2005
- Structural Basis for the Activity of Drugs that Inhibit PhosphodiesterasesStructure, 2004
- Gaussian docking functionsBiopolymers, 2002
- Fast, efficient generation of high‐quality atomic charges. AM1‐BCC model: II. Parameterization and validationJournal of Computational Chemistry, 2002